Cargando…
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
BACKGROUND: With the use of targeted drugs in lung cancer patients, targeted drug-induced interstitial lung disease (ILD) has attracted more and more attention. The incidence, time, and severity of different targeted drug-induced ILD vary. Almonertinib/HS-10296 is a third-generation epidermal growth...
Autores principales: | Zhou, Qian, Hu, Zhong, Li, Xin, Tang, Xiaokui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996844/ https://www.ncbi.nlm.nih.gov/pubmed/36890493 http://dx.doi.org/10.1186/s12890-023-02367-x |
Ejemplares similares
-
Almonertinib-induced interstitial lung disease: A case report
por: Jiang, Ting, et al.
Publicado: (2021) -
Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
por: Chen, Wenyan, et al.
Publicado: (2022) -
Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review
por: Wu, Longqiu, et al.
Publicado: (2021) -
Timolol-induced interstitial lung disease
por: Patel, Hetain, et al.
Publicado: (2015) -
Adalimumab induced interstitial lung disease
por: Aqsa, Anum, et al.
Publicado: (2020)